RY 160.91 0.3555% SHOP 116.03 -0.4718% TD 83.98 0.2148% ENB 62.82 1.4699% BN 68.81 1.6396% TRI 251.78 0.6959% CNQ 39.88 2.0732% CP 103.16 1.9771% CNR 137.31 0.483% BMO 129.32 0.4661% BNS 65.69 0.551% CSU 4682.54 -0.7613% CM 81.6 0.1473% MFC 39.65 -0.0252% ATD 71.3 1.3072% NGT 76.22 -1.6643% TRP 68.46 0.9586% SU 47.8 2.006% WCN 273.36 0.3156% L 213.68 0.1594%
The Offer
Company Overview
Apimeds US, a clinical-stage biopharmaceutical company, is advancing Apitox, a bee venom-based therapy derived from Apis mellifera, targeting inflammation and pain management for knee osteoarthritis (OA) and, to a lesser extent, multiple sclerosis (MS), leveraging clinical data from Apimeds Korea’s Apitoxin, approved in South Korea since 2003 for OA pain and mobility with no serious adverse events in a 2003–2009 post-marketing study. Following Apimeds Korea’s completion of Phase I, II, and III trials for OA, and a U.S. Phase III trial in 2018 involving 330 patients that showed therapeutic benefits but fell short of FDA approval due to a small sample size and data handling issues, Apimeds US is preparing a second Phase III trial to meet FDA standards, focusing on advanced knee OA patients (grades 2–4) to demonstrate efficacy. The Company remains optimistic about Apitox’s potential as an innovative treatment, supported by prior clinical results, and plans to extend its research to explore applications for MS, capitalizing on its proprietary venom processing and historical use in Asia and Europe for pain relief.
Xxxxxx Xxxxxx Xxxxxx
Xxxxxx Xxxxxx
Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .
Xxxxxx Xxxxxx Xxxxxx Xxxxxx & Xxxxxx
Xxxxxx Xxxxxx
Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .
Xxxxxx
Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .
Enter your details below and our team will help you to decide if this product is best for you.
The advice given by Kalkine Canada Advisory Services Inc. and provided on this website is general information only and it does not take into account your investment objectives, financial situation and the particular needs of any particular person. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. The website www.kalkine.ca is published by Kalkine Canada Advisory Services Inc. The link to our Terms & Conditions has been provided please go through them. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.
CA
NZ
UK
US
AU
IND
Please wait processing your request...